# Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

> **NCT02290951** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 200 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Odronextamab multiple dose levels
- **DRUG:** Odronextamab multiple dose levels

## Key facts

- **NCT ID:** NCT02290951
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-09
- **Primary completion:** 2025-08-21
- **Final completion:** 2025-08-21
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2025-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02290951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02290951, "Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02290951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*